[{"id":"ca62bd95-d966-4ef1-89f6-bb6e6f3f98af","acronym":"","url":"https://clinicaltrials.gov/study/NCT06432296","created_at":"2024-05-29T20:34:47.293Z","updated_at":"2024-07-02T16:35:00.222Z","phase":"Phase 3","brief_title":"Treatment of Malignant Ascites Caused by Advanced Epithelial Solid Tumors With M701 Bispecific Antibody","source_id_and_acronym":"NCT06432296","lead_sponsor":"Wuhan YZY Biopharma Co., Ltd.","biomarkers":" EPCAM","pipe":"","alterations":" ","tags":["EPCAM"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e M701"],"overall_status":"Recruiting","enrollment":" Enrollment 270","initiation":"Initiation: 03/20/2024","start_date":" 03/20/2024","primary_txt":" Primary completion: 08/03/2025","primary_completion_date":" 08/03/2025","study_txt":" Completion: 11/11/2025","study_completion_date":" 11/11/2025","last_update_posted":"2024-05-29"},{"id":"2a88a03e-1a74-4639-bea7-65d7f1196012","acronym":"","url":"https://clinicaltrials.gov/study/NCT05543330","created_at":"2022-09-16T15:56:39.623Z","updated_at":"2024-07-02T16:36:03.810Z","phase":"Phase 1/2","brief_title":"A Phase Ib/II Clinical Trial of M701 in the Treatment of Malignant Pleural Effusions Caused by NSCLC","source_id_and_acronym":"NCT05543330","lead_sponsor":"Wuhan YZY Biopharma Co., Ltd.","biomarkers":" EPCAM","pipe":" | ","alterations":" EPCAM expression","tags":["EPCAM"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EPCAM expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • M701"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 96","initiation":"Initiation: 09/30/2022","start_date":" 09/30/2022","primary_txt":" Primary completion: 06/01/2024","primary_completion_date":" 06/01/2024","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2022-09-16"},{"id":"0c72e324-a94b-4c79-b56d-8e07dee9bfbc","acronym":"CATUNIBLA","url":"https://clinicaltrials.gov/study/NCT04819399","created_at":"2021-03-29T12:52:24.159Z","updated_at":"2024-07-02T16:36:14.078Z","phase":"Phase 1","brief_title":"Investigation of Safety and Tolerability of Catumaxomab in Patients With NMIBC","source_id_and_acronym":"NCT04819399 - CATUNIBLA","lead_sponsor":"Lindis Biotech GmbH","biomarkers":" EPCAM","pipe":" | ","alterations":" EPCAM expression","tags":["EPCAM"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EPCAM expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Korjuny (catumaxomab)"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 07/07/2020","start_date":" 07/07/2020","primary_txt":" Primary completion: 12/30/2022","primary_completion_date":" 12/30/2022","study_txt":" Completion: 12/30/2023","study_completion_date":" 12/30/2023","last_update_posted":"2022-04-05"},{"id":"95ff12bc-e7be-49e9-8642-0f09820d5e2a","acronym":"BK2016.01","url":"https://clinicaltrials.gov/study/NCT03146637","created_at":"2021-01-19T14:08:20.070Z","updated_at":"2024-07-02T16:36:35.301Z","phase":"Phase 2","brief_title":"Study of Activated CIK Armed With Bispecific Antibody for Advanced Liver Cancer","source_id_and_acronym":"NCT03146637 - BK2016.01","lead_sponsor":"Benhealth Biopharmaceutical (Shenzhen) Co., Ltd.","biomarkers":" GPC3","pipe":"","alterations":" ","tags":["GPC3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e activated CIK and bispecific antibody • activated CIK-anti-CD3/MUC1/CEA/EpCAM/GPC3 antibody"],"overall_status":"Recruiting","enrollment":" Enrollment 80","initiation":"Initiation: 05/01/2017","start_date":" 05/01/2017","primary_txt":" Primary completion: 01/27/2021","primary_completion_date":" 01/27/2021","study_txt":" Completion: 01/28/2021","study_completion_date":" 01/28/2021","last_update_posted":"2021-02-01"},{"id":"07b4179f-e8ed-4410-a9f7-220b1ee391d8","acronym":"","url":"https://clinicaltrials.gov/study/NCT04501744","created_at":"2021-01-18T21:33:47.040Z","updated_at":"2024-07-02T16:36:42.300Z","phase":"Phase 1","brief_title":"A Study of M701 (EpCAM and CD3) in Malignant Ascites","source_id_and_acronym":"NCT04501744","lead_sponsor":"Wuhan YZY Biopharma Co., Ltd.","biomarkers":" CEACAM5 • MUC16 • AFP • CA 19-9","pipe":" | ","alterations":" CEACAM5 expression • MUC16 expression","tags":["CEACAM5 • MUC16 • AFP • CA 19-9"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CEACAM5 expression • MUC16 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e M701"],"overall_status":"Recruiting","enrollment":" Enrollment 42","initiation":"Initiation: 10/30/2018","start_date":" 10/30/2018","primary_txt":" Primary completion: 01/31/2021","primary_completion_date":" 01/31/2021","study_txt":" Completion: 06/30/2021","study_completion_date":" 06/30/2021","last_update_posted":"2020-08-06"},{"id":"d8b1c0e5-1ab7-4efb-a01f-9602158b973a","acronym":"","url":"https://clinicaltrials.gov/study/NCT01246440","created_at":"2021-01-18T05:01:11.794Z","updated_at":"2024-07-02T16:37:29.842Z","phase":"Phase 2","brief_title":"Catumaxomab as a Consolidation Therapy in Patients With Ovarian Cancer in Second or Third Clinical Disease Remission","source_id_and_acronym":"NCT01246440","lead_sponsor":"Grupo Español de Investigación en Cáncer de Ovario","biomarkers":" MUC16","pipe":"","alterations":" ","tags":["MUC16"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Korjuny (catumaxomab)"],"overall_status":"Completed","enrollment":" Enrollment 39","initiation":"Initiation: 06/01/2010","start_date":" 06/01/2010","primary_txt":" Primary completion: 02/01/2014","primary_completion_date":" 02/01/2014","study_txt":" Completion: 12/01/2014","study_completion_date":" 12/01/2014","last_update_posted":"2016-08-11"}]